Crossmark

Regional Citrate Anticoagulation Versus Systemic Heparin in Continuous Kidney Replacement Therapy: Examining the Role of Evidence in Health Technology Assessment

Crossref DOI link: https://doi.org/10.1007/s12325-025-03186-8

Published Online: 2025-04-16

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rognoni, Carla https://orcid.org/0000-0002-6330-0591
Pohlmeier, Robert

Tarricone, Rosanna
Funding

Funding for this research was provided by:

Fresenius Medical Care

Università Commerciale Luigi Bocconi
License Information

Text and Data Mining valid from 2025-04-16

Version of Record valid from 2025-04-16
More Information

Article History

Received: 4 March 2025

Accepted: 19 March 2025

First Online: 16 April 2025

Declarations

:

: Carla Rognoni and Rosanna Tarricone (CERGAS, SDA Bocconi School of Management) have nothing to disclose. Robert Pohlmeier is an employee of Fresenius Medical Care Deutschland GmbH.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below